<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:hpo ids='HP_0000554'>Uveitis</z:hpo> and <z:chebi fb="46" ids="15035">retinal</z:chebi> <z:hpo ids='HP_0002633'>vasculitis</z:hpo> are sight-threatening manifestations of <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease with limited treatment options </plain></SENT>
<SENT sid="1" pm="."><plain>This pilot study aimed to evaluate the safety, pharmacokinetics and clinical activity of XOMA 052 (gevokizumab), a recombinant humanised anti-interleukin 1β antibody, in <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease patients with <z:hpo ids='HP_0000554'>uveitis</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Patients with <z:hpo ids='HP_0011009'>acute</z:hpo> posterior or <z:hpo ids='HP_0012121'>panuveitis</z:hpo>, and/or <z:chebi fb="46" ids="15035">retinal</z:chebi> <z:hpo ids='HP_0002633'>vasculitis</z:hpo>, resistant to <z:chebi fb="2" ids="2948">azathioprine</z:chebi> and/or <z:chebi fb="0" ids="4031">ciclosporin</z:chebi>, and receiving 10 mg/day or less of <z:chebi fb="2" ids="8378">prednisolone</z:chebi>, were enrolled into the 98-day study </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="1" ids="35705">Immunosuppressive agents</z:chebi> were discontinued at baseline </plain></SENT>
<SENT sid="4" pm="."><plain>Patients received a single infusion of XOMA 052 (0.3 mg/kg) </plain></SENT>
<SENT sid="5" pm="."><plain>The safety and <z:hpo ids='HP_0000554'>uveitis</z:hpo> status and pharmacokinetics of XOMA 052 were evaluated </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Seven patients enrolled and completed the study </plain></SENT>
<SENT sid="7" pm="."><plain>No treatment-related adverse event was observed </plain></SENT>
<SENT sid="8" pm="."><plain>XOMA 052 treatment was associated with rapid and durable clinical response in <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="9" pm="."><plain>Complete resolution of intraocular <z:mp ids='MP_0001845'>inflammation</z:mp> was achieved in 4-21 days (median 14 days), with a median duration of response of 49 days (range 21-97 days); one patient remained exacerbation free throughout the study </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Well tolerated, XOMA 052 resulted in a rapid <z:hpo ids='HP_0003674'>onset</z:hpo> and sustained reduction in intraocular <z:mp ids='MP_0001845'>inflammation</z:mp> in patients with resistant <z:hpo ids='HP_0000554'>uveitis</z:hpo> and <z:chebi fb="46" ids="15035">retinal</z:chebi> <z:hpo ids='HP_0002633'>vasculitis</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>Moreover, the effect was observed despite discontinuation of <z:chebi fb="1" ids="35705">immunosuppressive agents</z:chebi> and without the need to increase <z:chebi fb="0" ids="50858">corticosteroid</z:chebi> dosages </plain></SENT>
</text></document>